cardiovascular outcomes in patients with drug eluting stents

26
Cardiovascular Outcomes in Patients with Drug Eluting Stents Undergoing Non-cardiac Surgery Boston Scientific Interventional Fellow, Royal Jubilee Hospital, Victoria, British Columbia Lecturer in Cardiology, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh NL Cruden , SA Harding, AD Flapan, C Graham, S Wild, R Slack, J Pell, DE Newby

Upload: simon23

Post on 21-Jul-2015

162 views

Category:

Documents


4 download

TRANSCRIPT

Page 1: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Cardiovascular Outcomes in Patients with Drug Eluting Stents Undergoing Non-cardiac

Surgery

Boston Scientific Interventional Fellow, Royal Jubilee Hospital, Victoria, British Columbia

Lecturer in Cardiology, Centre for Cardiovascular Science, University of Edinburgh, Edinburgh

NL Cruden, SA Harding, AD Flapan, C Graham, S Wild, R Slack, J Pell, DE Newby

Page 2: Cardiovascular Outcomes in Patients with Drug Eluting Stents

MY CONFLICTS OF INTEREST ARE

I am currently undertaking an Interventional Fellowship supported by Boston Scientific.

Page 3: Cardiovascular Outcomes in Patients with Drug Eluting Stents

“Trading Restenosis for Thrombosis”

Shuchman. NEJM 2006;355:1949-1952

Page 4: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Non-cardiac Surgery and Stent Thrombosis

Page 5: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Mortality and Non-cardiac SurgeryAuthors Year Type Time Period Patients

(n)DES(%)

Time from PCI to Surgery

Mortality Rate (%)

Kaluza et al 2000 RetrospectiveNon-randomised

1996 - 1998 40 0 <42d 21.4

Wilson et al 2003 RetrospectiveNon-randomised

1990 - 2000 207 0 <60d 3.4

Sharma et al 2004 RetrospectiveNon-randomised

1995 - 2000 47 0 <90d 18.4

Reddy et al 2005 RetrospectiveNon-randomised

1999 - 2004 56 0 ns 8.6

Leibowitz et al 2006 RetrospectiveNon-randomised

1995 - 2002 94 0 <90d 14.6

Vicenzi et al 2006 ProspectiveNon-randomised

2001 - 2004 103 ns <1y 5.7

Compton et al 2006 RetrospectiveNon-randomised

2003 - 2006 38 100 ns 2.5

Schouten et al 2006 RetrospectiveNon-randomised

1999 - 2005 192 52 <2y 3.1

Nuttall et al 2008 RetrospectiveNon-randomised

1990 - 2005 899 0 <1y 3.4

Rabbitts et al 2008 RetrospectiveNon-randomised

2003 - 2006 520 100 <2y 2.6

Adapted from Riddell et al. Circulation 2007;116:e378-382.

Page 6: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Adapted from Rabbitts et al. Anesthesiology 2008;109:596-604.

Page 7: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Aims

• To compare ischaemic cardiac outcomes in patients treated with DES or BMS undergoing non-cardiac surgery

• To examine the relationship between time from stent implantation to non-cardiac surgery and peri-operative cardiac outcomes

Page 8: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Methods

• Record Linkage

• Scottish Coronary Revascularisation Register

• Scottish Hospital Admissions Database– Patients undergoing PCI in Scotland between 1st

April 2003 and 31st March 2007 who subsequently underwent non-cardiac surgery.

• Follow-up until 31/07/2007

Page 9: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Methods

• Primary Endpoint:– In-hospital Death, MI or any IHD event (defined by

ICD code)

• Secondary Endpoints– In-hospital Death– In-hospital MI (defined by ICD code)

• Data analysis– Unpaired t-test or Mann-Whitney– Chi-squared or Fishers exact test– Multivariate Logistical Regression Model

Page 10: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Results

• 17,799 patients underwent 19,541 PCIs

• 1,953 patients who received a coronary stent subsequently underwent non-cardiac surgery

• At least 1 DES – 570 patients

• BMS alone - 1383 patients

Page 11: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Patient DemographicsAll BMS DES P

n=1953 n=1383 n=570Age, years [mean (SD)] 64 (10) 64 (10) 63 (11) 0.1

Male Sex 1267 (65%) 905 (65%) 362 (64%) 0.4

Diabetes Mellitus 287 (20%) 166 (18%) 121 (27%) <0.0001

Current Smokers 561 (30%) 385 (30%) 561 (33%) 0.1

Hypertension 990 (54%) 675 (52%) 315 (58%) <0.01

Previous Myocardial Infarction 605 (33%) 413 (32%) 192 (33%) 0.1

Peripheral Vascular Disease 139 (18%) 91 (18%) 48 (19%) 0.2

Renal Impairment 70 (4%) 43 (3%) 27 (5%) 0.1

Family History of IHD 680 (38%) 483 (38%) 197 (37%) 0.7

Previous CVA/TIA 113 (6%) 77 (6%) 36 (7%) 0.5

Previous CABG 204 (11%) 139 (10%) 65 (12%) 0.3

LVEF <30% 18 (1%) 15 (1%) 3 (<1%) 0.6

Indication

ACS 887 (45%) 655 (47%) 232 (41%) <0.001

Stable IHD 1066 (55%) 728 (53%) 338 (59%)

Page 12: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Index Procedural VariablesAll BMS DES P

n=1953 n=1383 n=570

Lesion Site LMS 35 (2%) 10 (1%) 25 (4%) 0.5RCA 645 (33%) 490 (35%) 155 (27%)

LAD 760 (39%) 492 (36%) 268 (47%)LCx 449 (23%) 338 (24%) 111 (20%)

Grafts 64 (3%) 53 (4%) 11 (2%)Number of stents 1 1575 (81%) 1151 (83%) 424 (74%) <0.0001

≥2 378 (19%) 232 (17%) 146 (24%)Stent Diameter (mm) ≤2.5 257 (13%) 104 (8%) 153 (27%) <0.0001

2.75 261 (14%) 143 (10%) 118 (21%)3.0 772 (40%) 576 (42%) 196 (34%)

3.5 471 (24%) 381 (27%) 90 (16%)4.0 + 192 (10%) 179 (13%) 13 (2%)

Length of Lesion (mm) <10 745 (38%) 585 (42%) 160 (28%) 0.810 to 20 765 (39%) 570 (41%) 195 (34%)

>20 443 (23%) 228 17%) 215 (38%)Lesion Calcification none 1703 (87%) 1220 (88%) 483 (85%) 0.01

moderate 189 (10%) 130 (9%) 59 (10%)severe 61 (3%) 33 (3%) 28 (5%)

Bifurcation Lesion 191 (10%) 132 (10%) 61 (11%) 0.4Ostial Location 101 (5%) 62 (5%) 39 (7%) <0.05

Chronic Total Occlusion 41 (2%) 16 (1%) 25 (4%) <0.0001Glycoprotein IIb/IIIa inhibitor 622 (32%) 431 (32%) 191 (34%) 0.8

Page 13: Cardiovascular Outcomes in Patients with Drug Eluting Stents

In-hospital Cardiac OutcomesInterval between PCI and non-cardiac surgery (Mean ± SD)

BMS - 577 ± 401 daysDES - 427 ± 294 days

P=0.3

P=0.8 P=0.3

Page 14: Cardiovascular Outcomes in Patients with Drug Eluting Stents

In-hospital Outcomes and Timing of Surgery

<42 days 42 days – 1 year >1 year P

n= 40 n=477 n=866

Death/Any IHD event 18 (45%)* 65 (13.6%)* 101 (11.7%)* <0.001

BMS

Death 2 (5%)† 5 (1%)† 1 (0.1%)† <0.0001

Myocardial Infarction 3 (7.5%)‡ 3 (0.6%)‡ 4 (0.5%)‡ <0.0001

<42 days 42 days – 1 year >1 year P

n= 19 n=255 n=282

Death/Any IHD event 7 (36.8%)* 41 (16.1%)* 35 (12.4%)* <0.01

DES Death 1 (5.3%)† 2 (0.8%)† 1 (0.4%)† <0.05

Myocardial Infarction 2 (10.5%)‡ 2 (0.8%)‡ 3 (1.1%)‡ <0.005

*p=0.7, †p=1.0, ‡p=1.0, BMS versus DES

Page 15: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Multivariate AnalysisPredictors of Death or IHD

• Previous Coronary Bypass Grafting OR 1.55 [1.07-2.26]

• Increasing Age OR 1.22 [1.06-1.39] for every 10 years

Page 16: Cardiovascular Outcomes in Patients with Drug Eluting Stents

When is it safe to operate?

Page 17: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Summary

• The risk of ischaemic cardiac events in patients with DES undergoing non-cardiac surgery does not differ from patients treated with BMS.

• In keeping with previous data, peri-operative cardiovascular risk is greatest where surgery is performed within 4-6 weeks of coronary stent implantation.

Page 18: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Limitations

• Retrospective

• Non-randomised

• No data on anti-platelet therapy

Page 19: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Thank you

Scott Harding

Andrew Flapan

David Newby

Contributors to the Scottish Revascularisation Register (R Slack, J Pell)

WTCRF Edinburgh (C Graham, S Wild)

Chief Scientist Office (Health Services Research Grant CZG/2/375)

Page 20: Cardiovascular Outcomes in Patients with Drug Eluting Stents
Page 21: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Surgical Procedures by Type

Page 22: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Primary Stent Type Frequency Percentage

CYPHER 140 24.6

TAXUS 389 68.2

ENDEAVOUR 27 4.8

DES NOT SPECIFIED 14 2.4

Drug Eluting Stents Used

Page 23: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Power Calculation

• Based on observed event rate of 10% in patients with BMS undergoing non-cardiac surgery and assuming a sample size of 1000 (n=500 in DES and BMS groups respectively)

• This study would have 80% power to detect a 5% absolute difference in the combined primary endpoint between the BMS and DES groups at the 0.05 significance level.

Page 24: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Codes Used

• ICD Codes• Acute myocardial infarction I210, I211, I212, I213, I214, I219, I220, I221, I228, I229

• Any IHD Event As above plus

Unstable angina I200, I201, I208, I209

Coronary thrombosis I240

Acute Ischaemic heart disease I249

Atherosclerotic heart disease I250, I251

• OPCS CodesA01-52, 57-69, 75; B1-31, 33-40; C1, 2, 5-9, 31-37; D1, 3, 10-12, 16-17; E1-4, 7, 8, 14-24, 39-41, 43-47, 53-58, 61; G1-13, 23-41, 49-53, 57-63, 68-74, 76-78; H1-19, 33-42, 57-61, 66; J1-5, 7-9, 18-23, 27-37, 54-65, 69-73; L1, 2, 4-8.4, 9-12, 16-25, 29, 30, 33-34, 37, 38, 41, 42, 45, 46, 48-53, 56-62, 65, 67, L68, 70, 74, 75.1, 77, 80 (NOT 80.3 OR 80.4), 81-85, 87, 90, 93, 98; M1-6, 8, 18-25, 34-41, 51, 52, 54, 55, 61-64, 72-75; N1, 5-9, 26, 28; P17, 18, 21-25, 32; Q1, 7-10, 20-39, 43-49, 52-54; R17; S1-3, S17-28, 33-39; T1-11, 15-27, 29, 30, 33-43, 50-77, 64-72, 76-80, 85-89, 92; V1-47, 49, 52-57; W1-34, 37-81, 82-89, 93-99; O6-10; X1-27

Page 25: Cardiovascular Outcomes in Patients with Drug Eluting Stents

In-hospital Outcomes & Timing of SurgeryDeath or any IHD Event

Death Myocardial Infarction

BMS

DES

Page 26: Cardiovascular Outcomes in Patients with Drug Eluting Stents

Chi-Square df pStent type 0.7 1 0.403Lesion 4.125 4 0.389Primary diagnosis 10.737 9 0.294No. stents [1, >1] 0.657 1 0.418Stent diameter 7.745 5 0.171Length of lesion 2.926 2 0.232Lesion Calcification 0.475 2 0.789Birfucation 1.461 1 0.227Ostial location 0.721 1 0.396Indication 5.307 7 0.623Procedure status 5.026 3 0.17Sex 0.283 1 0.595Diabetic 2.317 1 0.128Smoker 2.8 2 0.247Hypertension 0.176 1 0.675Previous MI 2.063 1 0.151PAD 0.613 1 0.434Renal status 6.026 3 0.127Fam. Hist. CAD 1.21 1 0.271LVEF 1.575 2 0.455GPIIbIIIa use 2.983 4 0.561Urgency of Surgery 3.612 1 0.057Vessel occlusion 6.039 2 0.049Previous CABG 7.128 1 0.008

T-Test No Event Death/IHD Event

p

Mean age, yrs (SD) 63.5 (10.3) 65.5 (9.5) 0.001

Univariate Predictors of Death/IHD